Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
62.24
-2.36 (-3.65%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,350,080
Profits / Employee
$279,466
Market Cap
6.57B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
CORT News
- 3 days ago - It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
- 11 days ago - Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
- 17 days ago - Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release - Seeking Alpha
- 17 days ago - Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha
- 18 days ago - Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
- 18 days ago - Corcept's ovarian cancer combination drug meets main goal in late-stage study - Reuters
- 18 days ago - Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation - Accesswire